Curasight (CURAS) Investor update summary

Capital Raise and Financial Outlook

• Launching a rights issue to raise up to DKK 100 million, extending cash runway into H2 2026 and supporting strategic flexibility for partnerships.

• Subscription period runs from May 2 to May 16, 2025, at DKK 1.98 per share, with 47% of the issue covered by commitments from partners and investors.

• Rights allocation: 43 rights per existing share as of May 1, 2025; 18 rights needed for one new share; investors can also apply for shares without pre-emptive rights.

• Outcome of the rights issue is expected to be published on May 21, 2025.

• Full subscription would raise approximately DKK 100 million before transaction costs.

Use of Proceeds and Development Milestones

• Funds will support phase I trial for uTREAT® in brain cancer and phase II trial for uTRACE® in prostate cancer, with key data readouts expected in H2 2025 and H1 2026.

• Additional proceeds will be used for pipeline development and working capital.

Clinical and Market Progress

• uTREAT® and uTRACE® platforms target glioblastoma and prostate cancer, with clinical trials planned or underway and strong preclinical efficacy data.

• Strategic partnership with Curium for prostate cancer diagnostics; over 400 patients have received uTRACE in investigator-initiated trials.

• Market potential estimated at EUR 5.1 billion annually for brain cancer therapy and EUR 1 billion for prostate cancer diagnostics.